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Abstract
Virtual screening (VS) overcomes the limitations of traditional high-throughput screening (HTS) by applying com-
puter-based methods in drug discovery. VS takes advantage of fast algorithms to filter chemical space and success-
fully select potential drug candidates. A key aspect in structure-based VS is the sampling of ligand-receptor con-
formations and the evaluation of these poses to predict near-native binding modes. The development of fast and
accurate algorithms during the last few years has allowed VS to become an important tool in drug discovery and
design. Herein, an overview of widely used ligand-based (e.g., similarity, pharmacophore searches) and structure-
based (protein-ligand docking) VS methods is discussed. Their strengths and limitations are described, along with
many successful stories. This review not only serves as an introductory guide for inexperienced VS users but also
presents a general overview of the current state and scope of these powerful tools.
Key words: high-throughput virtual screening, drug design, drug discovery, ligand-based, similarity searches,
pharmacophore, receptor-based, protein-ligand docking
Introduction to drug development and design
The process of drug development aims towards
the identification of compounds with pharmacological in-
terest to assist in the treatment of diseases and ultima-
tely to improve the quality of life. The compounds used
in pharmacology are mainly small organic molecules (li-
gands) which interact with specific biomolecules (recep-
tors/targets). Usually, compounds with some shared phy-
sico-chemical property or obtained according to a parti-
cular protocol are compiled into large collections that
are termed as libraries. Experimental identification of
small molecules with the desired activity can be achie-
ved by a high-throughput screening (HTS). Since the
drug-like libraries often contain millions of compounds,
their acquisition (e.g., by chemical synthesis) and effi-
cient testing by sophisticated robots is very expensive
(Plewczynski et al., 2010). A limitation that also reduces
the usability of HTS is its dependency on experimental
factors. For example, compounds selected for screening
should have high stability for long-term storage and high
solubility in the testing media.
An alternative to experimental HTS is high-through-
put virtual screening (HTVS or VS), which has become
a standard tool in medicinal chemistry (Leach et al.,
2006). Virtual screening (VS) uses computational power
to test large sets of chemical compounds in a few days at
low costs. Moreover, not only real compounds but also
purely theoretical ones can be included in the virtual li-
brary and screened in silico. This is a very powerful
feature that allows purchasing or synthesizing only a re-
duced set of selected compounds thus reducing the cost
and time of the entire study significantly.
Several screening campaigns have been launched to
compare results of virtual and experimental approaches
(Doman et al., 2002; Evensen et al., 2003; Jenkins et al.,
2003; Paiva et al., 2001). These results suggest that VS
may complement HTS and successfully identify false-
negatives produced by experimental testing in order to
increase the hit rate (Doman et al., 2002). Even though
HTS has proven to be quite beneficial in identifying
compounds with greater structural diversity compared
to VS (Paiva et al., 2001), in some cases virtual hits are
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Table 1. Classification of virtual screening methods based on the amount and type of information available
about the system under inspection
Known ligand(s) Unknown ligands
Known structure of target 
or close homologue
structure-based virtual screening:
protein-ligand docking
de novo structure-based virtual screening:
protein-ligand docking
Unknown target structure
ligand-based virtual screening:
few ligands: similarity searches
several ligands: pharmacophore searches
virtual screening cannot be applied
found to be better drug candidates than the experi-
mental ones (Brenk et al., 2005). 
In contrast to high-throughput screening, VS is
a knowledge-driven approach. The quality and the amo-
unt of information regarding the system under inspec-
tion is a critical factor when designing a computer-assis-
ted drug design experiment (Klebe, 2006) – see Table 1.
Knowledge about the substrates may be the starting
point to retrieve similar compounds by 2D/3D similarity
or pharmacophore searches (see section Pre-filtering).
In cases where the target structure is available, docking
methods that sample ligand poses with respect to the
receptor binding site can be used (see section Protein-
ligand docking). 
This paper presents an overview of VS methods and
applications, starting with the discussion on strategies
for the preparation of ligand libraries. The selection of
appropriate sets of small molecules for screening is a de-
manding task requiring adequate filtering strategies, for
example, similarity searches by fingerprints or pharma-
cophores. The review also points toward the strengths
and weaknesses of target-based VS methods. Finally,
successful cases of VS campaigns are introduced to high-
light the ability of the presented technique to assist
in the drug discovery process. 
Pre-filtering 
The virtual hunt for bioactive compounds is a se-
quential process (Bajorath, 2004), which is preceded by
a suitable compound library design. Thanks to the widely
available molecule collections, chemical information is
accessible for almost every scientist. Despite this wide
accessibility, the most striking question remains: which
chemical molecules are of interest and should be chosen
for a VS procedure? 
The chemical space is vast, but most of it remains
biologically uninteresting (Shoichet, 2004). It is neces-
Fig. 1. Presentation of “perfect drug” properties of pharmaceu-
tical compounds, and their relation to the bioavailability in hu-
mans (ADME properties) and to the Lipinski’s Rule of Five
sary to filter the compounds to obtain those with a high
likelihood of bio-medical relevance. It is still unknown
how to exhaustively screen the vastness of the chemical
space and create diverse and balanced drug-like libraries
(Klebe, 2006). However, a number of limitations exist in
achieving the same. A wide range of filters may be ap-
plied to discredit compounds with unfavorable pharma-
codynamic or pharmacokinetic properties (Varnek and
Tropsha, 2008). Taking into account the knowledge-
driven nature of VS, all data concerning liganda and tar-
get structure should be included in the filtering step, e.g.
information regarding active compounds (substrates,
known inhibitors), receptor structure and receptor-li-
gand interactions (Walters et al., 1998). The VS method
takes advantage of all available biological information,
which when annotated in chemical libraries may help to
define nontoxic and biologically interesting molecules.
Experimental data about toxicity, affinity or ADME (Ab-
sorption, Distribution, Metabolism and Excretion) pro-
perties (see Figure 1) are typically taken into account
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when designing libraries of small molecules. However,
even though the filtering methods ensure fast identifi-
cation of molecules that are likely to be biologically re-
levant (Gasteiger, 2003), they also risk the omission of
potentially interesting compounds with diverse and
novel structure.
In the following section, commonly used methods
and applications of ligand-based strategies are presen-
ted. First, a focus is put on the commonly applied drug-
like filters and their performance in compound selection,
and then similarity searches and the corresponding tools
are introduced as an efficient way to retrieve bioactive
molecules. The validity of the hereafter presented strate-
gies has been proven by the successful application of VS
workflows.
Filtering by drug-like properties
There is a series of requirements for organic mole-
cules for meeting drug-likeness criteria. Compounds are
usually considered as drug-like if they fulfill the Lipin-
ski’s Rule of Five and the ADME restrictions (Figure 1).
This “rule of thumb” was formulated after the observa-
tion that most drugs are small, lipophilic molecules. This
specifies drug-like requirements for molecular weight,
hydrogen bonding capabilities, solubility and ADME
properties. Other validation methods take into account
the number of rotatable bonds, aggregation, polar sur-
face area (Mestres and Knegtel, 2000) or a composition
of, exclusively, bioelements (e.g. H, C, N, O, P, S, Cl, Br)
(Bohacek et al., 1996). It is also necessary to consider
information about ligand flexibility, which is the key
factor in finding the ligand’s spatial orientation within
the receptor cavity. Thus, a “perfect drug” structure
should be carefully balanced between flexibility and rigid-
ness. The compound may lose binding specificity be-
cause of numerous rotatable bonds, while rigid rings or
constrained scaffolds can lead to binding inability. More-
over, while designing potential chemicals, it is also im-
portant to exclude all structural features known to have
unfavorable influence on an organism (i.e. known toxic
chemical groups). There are many other filtration cri-
teria (Gleeson, 2008), which may be applied in pre-filte-
ring of compound libraries, but the main conclusion re-
mains the same: when creating a data set of chemicals
for VS purposes, it is advised to take into consideration
at least basic drug-like criteria to guard against scre-
ening of chemical spaces that are too large.
Chemical similarity searching
Ligand-based similarity methods rely on the basic
paradigm that structural likeness enhances the chances
to share a common bioactive profile. Thus, selecting
compounds similar to known drugs increases the possi-
bility of choosing a potential lead (Willet, 1998). It is
common to use similarity searches in the identification
of compounds based on their similarity to active ones.
Moreover, this concept may be used when creating “tar-
geted” libraries containing compounds similar to at least
one true binder to its specific receptor (e.g., a substrate,
inhibitor or cofactor). Based on a structural similarity
search among small molecules, it is possible to retrieve
compounds containing identical substructures that share
affinity to the same receptors. This tendency is reflected
by the term of privileged structures (Evans et al., 1988),
which explains the role of the substructures/scaffolds
that may exhibit dependencies for a particular target
space (e.g., ligands with high affinity for certain target
family representatives). A recent analysis have demon-
strated (Schnur et al., 2006) that such dependencies are
not necessarily translated into the level of chemical func-
tionalization of the scaffold, and only a narrow range of
substructures are selective for a specific target family/
group. Still, it is important to keep in mind that certain
substructures are repeatedly found in databases of
known drugs and seem to be “well-defined islands” in
the lead-like chemical space (Ertl et al., 2006). In the
chemical similarity search, three-dimensional properties
of compounds may be also included. When using 3D
descriptors, it is possible to apply information about
a ligand’s shape and obtain useful information regarding
possible interactions (Zauhar et al., 2003). Data descri-
bing the shape of a small molecule can be equally retrie-
ved from known binder structures or features in the bin-
ding pocket of the receptor (Bender and Glen, 2004;
Willet, 1998; Zauhar et al., 2003). 
Generally, when analyzing biological systems, nei-
ther active compounds nor the binding mode of the na-
tural cofactors are known. If there is no structural infor-
mation to be used in the similarity searches, it is pos-
sible to define preferable ligand binding modes, by scre-
ening vast and structurally diverse libraries of compo-
unds. In accordance to the funnel strategy (Beautrait et
al., 2008), vast amount of chemical data are first studied
to extract a smaller set of compounds. Thereafter, this
set is analyzed in more detail. Using structurally diverse
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libraries, more varied results may be obtained, showing
novel and innovative chemical structures. Structurally
diverse scaffolds selected by this method need to be
further analyzed and optimized for the identification of
interesting chemical structures. 
How to filter? 
We have already described filtering concepts based
on drug-like properties, similarity and diversity measu-
res. But what are the exact tools and strategies to be
taken into consideration in order to achieve high effi-
ciency of similarity searches?
Introduction to fingerprints
A key aspect for ligand-based filtering is the selection
of appropriate molecular “fingerprints”, which may be de-
fined as a mathematical representation of the molecules.
In other words, the chemical information of the compound
is translated into data that can be easily understood and
processed by the computational methods. The main stren-
gth of this approach lies in its ability to compare multi-
ple fingerprints and compute their similarity by using
e.g. the Tanimoto coefficient (Hamersa et al., 2002),
which greatly facilitates similarity searches. In VS, fin-
gerprints can be used to screen the database identifying
compounds that match the features of a single bioactive
ligand.
Fingerprints may be classified according to their
dimensionality ranging from one dimensional (1D) to 3D
(Bender and Glen, 2004) – see Table 2 and Figure 2.
Among all commonly used, the most popular and effi-
cient are 2D fingerprints. They range in the family of
simple 2D substructure sketches, graph-based repre-
sentations and more important, bit strings. In the latter
type, molecules are represented by a sequence of zeros
and ones that reflect the presence or absence of certain
structural features (e.g. substructure, bond, torsion
angle) and transformed into a hashed number. More-
over, 2D fingerprints are considered more successful in
retrieving active compounds than 3D shape or docking
methods (Zhang and Muegge, 2006). 
Pharmacophores
When disposing three-dimensional information about
the ligand and/or receptor atomic structure, it is pos-
sible to take advantage of pharmacophore-based me-
thods, which use geometric and topological constraints.
This approach is based on ligand-receptor 3D dependen-
cies and stereo-chemical rules that determine the pre-
ferred binding mode. Ligand-based pharmacophore is
usually defined as a relational model of features that are
common for ligands interacting with the same receptor.
The above-mentioned features usually include hydrogen
bonding donors and acceptors, charged groups and aro-
matic rings. Spatial relationships of pharmacophoric fea-
tures can be then easily transformed into 3D coordinates
and distances, which may form a basis for similarity sear-
ches. This approach is recommended when disposing
information about a set of ligands for a given target with-
out a solved 3D structure. In such a case, details about
a target binding site should be retrieved from known bin-
ders and used in pharmacophoric screening. Pharmaco-
phore-based strategies are widely applied in screening
projects and in some cases outperform docking results
(Chen et al., 2009b).
Interaction fingerprints (IFP) 
Klebe introduced the concepts of “forward” and
“backward” filtering (Klebe, 2006). The former one re-
fers to applying hierarchical filtering methods prior to
docking (including drug-like features and/or structure-
based pharmacophore), to significantly reduce the amo-
unt of data to be screened. Conversely, “backward” filte-
ring starts with a high-throughput docking and focuses
on post-docking strategies as a subsequent step. The
latter approach was recently employed in the interaction-
based filtering of ligand poses generated during docking
(Marcou and Rognan, 2007). Interaction fingerprint
(IFP) translates 3D information about protein-ligand
interaction into a bit vector that can be easily compared
with other fingerprints. IFPs – which details the inter-
action of a known binder with a target structure – may
be treated as a reference to assess other ligand-target
poses (e.g. docking results). Using IFPs allows retrieval
of compounds that form interactions similar to the true
binding modes. Thus, including usage of IFPs into a VS
procedure may significantly improve the docking result
analysis and lead to identification of new interesting
compounds. 
Success stories
There are several successful VS stories involving
2D/3D fingerprinting methods (Mohan et al., 2005).
Fingerprints can be used at the first stage of the project
to create a set of chemical compounds with the desired
properties. A library focused on a specific biological sy-
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Table 2. Specification of small-molecule descriptors
Space Character Description
1D general
global properties retrieved from chemical formula with no need of 2D/3D structure 
(e.g. molecular weight, number and types of atoms/bonds, number of rings, logP)
2D topological
variety of the fragmentation strategy (e.g. type of connectivity, atom paths, appearance of frag-
ments), or substructures (e.g. maximum common substructure)
3D three dimensional shape, interaction-based pharmacophores, receptor-based pharmacophore
Fig. 2. Fingerprints as ligand descriptors. Depending on the information type they may range from one to three dimensional.
Based on the work by Rognan, 2007
stem is obtained by selecting compounds that meet spe-
cific structural/chemical requirements (for example, li-
gands containing a specific substructure able to match
the structural requirements of the receptor binding poc-
ket). Using such a library allows for more accurate analy-
ses and reduces computational demands during the doc-
king step. The above-mentioned approach was followed
in the discovery of leads for the human carbonic an-
hydrase II (Gruneberg et al., 2002), where 2D substruc-
ture searches and 3D pharmacophore queries combined
with docking methods were successfully used in the se-
lection of inhibitors. The activity of virtually identified
compounds was then confirmed experimentally. The phar-
macophore features can also be derived from the target
structures analysis (receptor-based pharmacophore).
More precisely, a binding site analysis may help to
identify regions of favorable protein-ligand interaction.
This approach, with subsequent docking procedure, was
successfully applied in the discovery of novel inhibitors
of the alanine racemase (Mustata and Briggs, 2002) and
Plasmodium falciparum hydrofolate reductase (Rastelli
et al., 2003).
Final steps
Having chosen a set of organic molecules for VS, we
move to the preparation stage. Considering a situation
where fingerprints or chemical formula are the only
available information about the ligand (for example in 2D
searches) its spatial coordinates should be defined.
The 3D structure can be obtained from online databases
containing structural information from crystallogra-
phic/NMR experiments, like the Cambridge Structural
Database (Allen, 2002) (CSD: 541,748 small molecule
structures as of January 2011) or the Protein Data Bank
(Berman et al., 2000) (PDB: 10,263 structures with
bound ligands as of December 2010). Another option is
to transform 1D/2D information into 3D spatial coordi-
nates using commercial methods (for example, CORINA
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(Sadowski et al., 1994) or open-source packages, like
OpenBabel (Guha et al., 2006). The methods designed
to build low-energy 3D models may usually take advan-
tage of the already known properties of molecules de-
posited in the PDB or CSD (data on bond lengths, an-
gles, torsions or molecular fragments).
Before applying the docking procedure, physico-che-
mical properties for the selected ligands need to be as-
signed: protonation states, tautomers and stereoiso-
mers. Although default charges are assigned to meet
standard biological conditions (pH 7), it is possible to
model lower or higher pH. Thus, focused libraries (Wal-
ters et al., 1998) can be created to meet specific require-
ments for certain target structures (e.g. positively or
negatively charged binding pockets). 
The importance of the ligand preparation step is of-
ten underestimated and may easily lead to false-positive
predictions in VS campaigns (Brenk et al., 2005). It is
advisable to use the already prepared and compiled
small molecule collections known as “ready-to-dock ” li-
gand libraries. ZINC (Irwin and Shoichet, 2005) is a wi-
dely used, freely available database that contains millions
of small ligands that can be used in VS. The 3D coordina-
tes of compiled compounds can be downloaded with
their protonation states and atomic charges already as-
signed. Using “ready-to-dock ” sets may significantly im-
prove the quality of results, especially when used by
inexperienced researchers. 
Current state, challenges and successful stories
in structure-based virtual screening
The amount and quality of available information on
the system under analysis is a key factor when designing
a VS project (Klebe, 2006) – see Table 1. If the 3D struc-
ture of the macromolecule of interest is known, the co-
ordinates of the features contained in the target region
are valuable data and can be used to improve the quality
of results. Exemplary methods of obtaining 3D models of
biomolecules include NMR spectroscopy, X-ray crystallo-
graphy or homology modeling. In the last case, the sol-
ved structure from at least one closely related homo-
logue is a sine qua non requirement. Currently, PDB
contains more than 70,000 experimentally solved 3D
structures of proteins that can be used as targets in VS
and in homology modeling. NMR spectroscopy obtains
several real conformations for the receptor while X-ray
crystallography offers one single state of the crystallized
protein. Even though all these methods have been suc-
cessfully applied in structure-based VS, X-ray crystallo-
graphy remains the most powerful source of structural
data.
In this section, we focus on the in silico approaches
that profit from 3D structural features encoded in the
interaction interface to perform VS. First, an overview
of the current state and widely used software is presen-
ted along with several recently published success stories
in computer-assisted drug design. This is followed by
a detailed description of the VS process, focusing on the
recent challenging aspects in the field that still remain
the bottlenecks of this method.
The protein-ligand docking (PLD) problem
The aim of a PLD experiment is to predict the 3D
structure formed upon the mutual binding of two or
more molecules. For this purpose, two complementary
components are required: 1) a method that samples the
conformational space of the ligand with respect to the
target (ideally: also by sampling the internal conformatio-
nal space of one or both of these molecules) thereby
generating target-ligand poses and 2) a mathematical ex-
pression (the scoring function – SF), which evaluates the
proposed poses according to the potential binding
strength (Leach and Gillet, 2007). Both aspects affect
the quality of the results. While the generation of poses
should ensure that most of the conformational space is
explored, the scoring function should efficiently evalu-
ate each of the poses and identify active compounds and
near-native conformations. In practice, these two funda-
mental components limit the applicability of the ap-
proach, provided that for an effective high-throughput
docking (HTD) a compromise between speed and ac-
curacy is achieved.
Over the years, many small molecule docking me-
thods have been developed and reviewed (Cross et al.,
2009; Kellenberger et al., 2004; Kirchmair et al., 2008;
Moitessier et al., 2009; Plewczynski et al., 2011a). They
have been applied not only to protein-ligand scenarios but
also in RNA-ligand docking (Chen et al., 1997; Filikov et
al., 2000; Lang et al., 2009; Leclerc and Cedergren,
1998), DNA-ligand docking (Dailey et al., 2009; Ricci and
Netz, 2009) and to the modulation of protein-protein inter-
actions (Casey et al., 2009; Meireles and Mustata, 2011).
They are commonly referred to as ligand-docking soft-
ware. Several widely used docking implementations are
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Table 3. A list of widely used protein-ligand docking software (Sousa et al., 2006). The main strengths and weaknesses are based
on the work by Kellenberger et al., 2004, and the selection of targets studied by high-throughput virtual screening is followed by
favorable experimental testing. GA stands for Genetic Algorithm, HF for Hierarchical Filtering, IC for Incremental Construction,
MA for Matching Algorithm and MC for Monte Carlo sampling (Moitessier et al., 2009)
Program
and algorithm
Strengths Weaknesses Examples of recent successful virtual screening experiments
AutoDock
and AutoDock Vina
(Morris et al., 1998;
Osterberg et al., 2002;
Trott and Olson, 2010) 
– GA
small ligands
large binding sites
freely available 
accuracy in highly
flexible ligands
low speed
Glutamate Transporter 1 (GLT1) inhibitors (Luethi et al., 2010)
Cdc25 phosphatase inhibitors (Park et al., 2008)
D-Ala:D-Ala ligase inhibitors (Kovac et al., 2008)
Cyclodextrin-based receptors (Steffen et al., 2007)
DOCK 
(Ewing et al., 2001;
Kuntz et al., 1982;
Lang et al., 2009;
Moustakas et al., 2006;
Oshiro et al., 1995)
– IC
small binding sites
opened cavities
small hydrophobic ligands
freely available 
accuracy in highly
flexible ligands
highly polar ligands
Hepatitis C virus helicase inhibitors (Chen et al., 2009a)
SARS-CoV 3C-like proteinase inhibitors (Liu et al., 2005)
Cyclooxygenase (COX-2) inhibitors (Mozziconacci et al., 2005)
FlexX 
(Rarey et al., 1996)
– IC
small binding sites
small hydrophobic ligands
very flexible ligands
Bacterial NAD synthetase inhibitors (Moro et al., 2009)
Lymphoid phosphatase inhibitors (Wu et al., 2009)
RNA polymerase inhibitors (Kim et al., 2008)
ATP phosphoribosyltransferase (HisG) inhibitors (Cho et al., 2008)
Human histamine H4 receptor ligands (Kiss et al., 2008)
Glide 
(Friesner et al., 2004)
– HF+MC
flexible ligands
small hydrophobic ligands
ranking for very polar
ligands low speed
Liver X receptor modulators (Cheng et al., 2008)
HIV-1 reverse transcriptase inhibitors (Barreiro et al., 2007)
GOLD 
(Verdonk et al., 2003;
Verdonk et al., 2005)
– GA
small binding sites
small hydrophobic ligands
buried binding pockets
ranking
for very polar ligands
or large cavities
HIV-1: CD4-gp120 binding inhibitors (Lalonde et al., 2011)
Serotonin 5-HT(7)R antagonists (Kurczab et al., 2010)
Non-peptide β-secretase inhibitors (Xu et al., 2010)
Sarco/endoplasmic reticulum calcium ATPase inhibitors 
(Deye et al., 2009)
Trypanosoma cruzi trans-sialidase inhibitors (Neres et al., 2009)
Surflex 
(Jain, 2003; Jain, 2007)
– IC+MA
large and opened cavities
small binding sites
very flexible ligands
low speed
for large ligands
Triple helical DNA intercalators (Holt et al., 2009)
ErmC methyltransferase inhibitors (Feder et al., 2008)
Hepatitis C virus NS5B polymerase inhibitors (Musmuca et al., 2010)
summarized in Table 3 (Sousa et al., 2006). Although
most of them require a commercial license, academic
users and researchers can experiment using freely avai-
lable software like DOCK (Lang et al., 2009) or Auto-
Dock Vina (Trott and Olson, 2010). Each docking prog-
ram has its own algorithms for the generation and sco-
ring of the ligand poses, and as a result exhibits indivi-
dual strengths and weaknesses for specific ligands (see
Table 3) and/or targets (Cross et al., 2009). While most
of the software available performs poorly in generating
near native poses for highly flexible ligands, Glide soft-
ware (Friesner et al., 2004) overcomes this issue by run-
ning a more accurate search along the conformational
space (random search followed by structure refinement),
which results in an overall slow speed.
Although the available methods are far from being
perfect, their applicability in high-throughput VS has
been largely demonstrated and reported. Table 3 sum-
marizes recent VS campaigns performed using each of
the implementations followed by experimental confirma-
tion of the identified hits. It is worth noting that diver-
gence among the targeted receptors (several protein
families, RNA, DNA) indicates that each of the methods
reported here represents a valuable tool in drug design
that can manifest itself in different types of the system
under examination. For example, the discovery and ex-
perimental confirmation of novel quinolone-based triple
helical DNA intercalators (Holt et al., 2009) were based
on using Surflex software (Jain, 2007). The compounds
identified in that experiment were found to selectively
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bind the triplex DNA poly(dA)-[poly(dT)]2 in the in vitro
tests. Recently, our group also used Surflex to identify
potential inhibitors of the ErmC’ methyltransferase
which is responsible for bacterial resistance against
macrolide antibiotics (Feder et al., 2008). Further ex-
perimental tests of the best scored docking ligands
positively identified eight active compounds. Another
interesting VS experiment revealed novel potential non-
peptide inhibitors for the β-secretase (Xu et al., 2010).
After running a VS experiment with GOLD (Verdonk et
al., 2003), in vitro testing demonstrated not only high
affinity for the receptor but also low cytotoxicity against
neuroblastoma cells. This discovery provides new che-
mical entities that target an enzyme that is of great in-
terest in the treatment of Alzheimer's disease. More
examples of successful in silico assisted drug design sto-
ries can be found in the exhaustive research book Suc-
cess Stories of Computer-Aided Design (Kubinyi, 2006).
Designing a high-throughput docking experiment
A high-throughput docking (HTD) experiment aims
to identify active compounds from large libraries of pos-
sible ligands. The general steps are shown on the sche-
matic Figure 3. Being a knowledge-driven approach,
structure-based VS requires three-dimensional informa-
tion about the binding pocket of the receptor. As mentio-
ned earlier, this information can be collected from ex-
perimental or computational sources. When choosing
a receptor structure for docking, careful inspection of
the physico-chemical properties of the pocket is advised.
The pocket size and shape must be suitable for docking
and should consist of chemical groups able to tightly in-
teract with the ligand (mainly charged and hydrogen-
bond donors/acceptors) (Pérot et al., 2010). If true bin-
ders are known, a comparison of the docked poses and
their affinities with experimental data is strongly recom-
mended. For targets in which the location of the binding
pocket is unknown, annotated homologue proteins based
tools like AnnoLyze (Marti-Renom et al., 2007) can be
used to predict the binding region of small ligands.
After the selection of the binding pocket, a careful
preparation of the structure should be carried out;
the undesired solvent and cofactors deleted, the protona-
tion state for each amino acid determined and the hydro-
gen atoms must be added accordingly, and the charge
for each atom should be specified. Chimera (Pettersen
et al., 2004) is a freely available structure viewer (for
academic purposes) that can be used for automated
preparation of molecules.
The preparation of ligand libraries has already been
discussed in the previous section. Several approaches
can be followed to generate ligand libraries suitable for
HTD. As shown in Table 1, if there are known binders,
a similarity or a pharmacophore search can be perfor-
med in order to generate a library of compounds that
retain the physico-chemical properties of the ligands.
Otherwise, general libraries that include diversity from
the vast chemical space should be selected.
Prior to docking, the 3D coordinates, protonation
states and charges of the ligands included in the ge-
nerated library must be defined (see section Pre-filtering
-- Final Steps). If the compounds are gathered from
“ready-to-dock ” libraries, this step can be omitted. 
High-throughput virtual screening: a useful tool 
for in silico drug discovery
After selecting and preparing the target and the li-
gands for screening, a PLD software and methodology
should be chosen. Given that each implementation has its
own specific features (see Table 3), this is a crucial step
in structure-based VS. Since the first version of DOCK
was made available in 1982, many changes have been
introduced to PLD methods. Initially, both the target and
the ligand were treated as rigid entities during the gene-
ration of poses, simplifying the space of possible protein-
ligand complexes to a six-dimensional problem (three ro-
tations and three translations). The rigidity imposed du-
ring this so-called “rigid-body” docking reduces the com-
putational requirements dramatically. However, the con-
formations of both the ligand and receptor are altered
upon the formation of the complex and, therefore, most
of the rigidbody docking tools are not able to accurately
reproduce the experimental observations. As a result,
most of the current implementations take into account
ligand flexibility by default. 
In the DOCK and Surflex software, an “anchor-and-
grow” algorithm divides the ligand into rigid fragments
and docks the largest fragment into the binding pocket.
The rest of the fragments are bound sequentially to
the anchor in order to maximize the score of the final
conformer. Another option is to generate and evaluate
the poses on-the-fly. This is the case in the ICM (Abag-
yan et al., 1994) software, which uses the Metropo-
lis/Monte-Carlo algorithm to generate random poses and
Virtual screening strategies in drug design – methods and applications 257
Fig. 3. Proposed workflow in a high-throughput docking ex-
periment. Shadowed steps are covered in this paper. 1) A bio-
logically relevant target modulated by a small ligand is identi-
fied and 2) a model of its 3D structure is obtained. 3) A model
for the selected receptor is prepared. 4) A library of small che-
mical compounds is selected and, if needed, 5) prepared for
the virtual screening process. The information regarding
the nature of the target and the compounds to be screened
can be used to 6) select the appropriate protein-ligand docking
software and method. After 7) screening the compounds, seve-
ral methods have been developed to 8) post-process the re-
sults and assist in 9) the identification of possible hits. Finally,
10) the identified hits are purchased or synthesized, and their
activity is validated by experimental testing
guide the exploration. There are other methods, such as
AutoDock and GOLD, which rely on a genetic algorithm
to explore the conformational space of the system. Ini-
tially, the coordinates of ligand fragments are randomly
mixed. The new conformations are evaluated and ran-
ked, and the highly scored ones are selected to build
the next “generation” of poses. To ensure an appro-
priate sampling of the conformational space, this process
is repeated millions of times for each ligand. In HAD-
DOCK (Dominguez et al., 2003) software, an initial rigid-
body search is performed to screen poses rapidly, and it
is followed by a minimization to accommodate the ligand
into the binding pocket. An interesting feature in this
implementation is the possibility of using knowledge
about the target-ligand binding mode to define a set of
distance constrains. A complete analysis of implementa-
tions and algorithms has been recently reported (Moites-
sier et al., 2009) and may serve as a detailed guide for
algorithms involved in VS. 
A method that allows experimentation in VS without
dealing with large highly flexible ligands relies on so-cal-
led fragment-based VS (Feyfant et al., 2011; Na and Hu,
2011). In this approach, instead of docking the entire
structure of the ligands, libraries of chemical fragments
are prepared and docked into the pocket, thus allowing
for fast screen of large and diverse sets of compounds.
After screening, the selected fragments can be used as
scaffolds to retrieve ligands from the database. This
method has been successfully applied in the in silico
drug discovery of novel compounds (Englert et al., 2010;
Hartenfeller and Schneider, 2011). For example, novel
fragment inhibitors of class 1 phospatidylinositide 3-
kinases were reported to use a homology modeled
receptor (Giordanetto et al., 2011). Experimental testing
confirmed the potency of compounds belonging to
several different structural classes.
In many real cases, rearrangements in the receptor’s
binding pocket upon complex formation have been ob-
served. Moreover, they dramatically affect the accuracy
of the prediction of binding modes and affinities, and re-
quire a proper treatment of flexibility for both the ligand
and receptor during the VS (Lin, 2011; Totrov and
Abagyan, 2008). This is a particularly challenging aspect
in HTD due to the dimensionality of the conformational
space, which significantly influences the efficiency of
screening. The fastest way to model target flexibility
relies on the use of “softer” scoring functions. The
weight of the intermolecular clashing atoms is lowered
and allows a deeper penetration of the ligand into the
target surface. Another method that can be used in such
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cases is the so-called multiple receptor docking. In this
procedure, the ligands are sequentially docked into an
ensemble of conformations for the target, from which
the best scored poses are selected (Popov et al., 2007).
It is noteworthy that each additional conformation used
in an HTD experiment increases the chance of retrieving
false positives, and therefore a careful and critical ana-
lysis of the results is advisable. The conformations
needed for multiple receptor docking can be obtained di-
rectly from NMR spectroscopy or multiple X-ray crystal-
lography, or may be selected from the frames obtained
in a Molecular Dynamics simulation or by means of
the Normal Mode Analysis (Sperandio et al., 2010).
Computational resources limit an explicit treatment of
receptor flexibility in HTD. Generally, a few side-chains
in the binding pocket are selected to be flexible and
their conformational space is explored during docking.
There are several approaches to this principle. For
example, while AutoDock Vina performs an exhaustive
search for each active rotatable bond, other algorithms
select on-the-fly the conformations to be screened by
taking into account the physical features of the pocket
(e.g. SLIDE – see Zavodszky and Kuhn, 2005). The con-
formations for the side-chains can also be directly ob-
tained from external libraries of rotamers. In the case of
Surflex, after rigid receptor docking, the binding pocket
is shortly optimized to accommodate the ligand, and
the pose is re-scored. After pocket adaptation, significant
improvements in the binding mode prediction were
reported (Jain, 2009). Figure 4 shows the result of a doc-
king experiment performed using the Surflex.
Limitations of widely used PLD routines related to
the efficiency and sensibility to ligand and receptor na-
ture have already been discussed and summarized in
Table 3. The consistency of the methods can be affected
by several random factors. For example, in SLIDE and
QXP (McMartin and Bohacek, 1997) the input coordina-
tes of the ligands were found to have an impact on
the docking pose (as could be seen in te experiment)
(Kellenberger et al., 2004). Effect of physico-chemical
properties of ligands such as protonation, tautomerism
and isomerism have been recently analyzed in the doc-
king results (ten Brink and Exner, 2009). The inclusion
of such modifications to extend ligand libraries remains
an area of active research. Even though these features
are known to play an important role in binding, current
scoring functions are generally unable to handle such
Fig. 4. Crystallographic pose and predicted binding mode of
the inhibitor sinefungin (Schluckebier et al., 1999) in the bin-
ding pocket of ErmC’ methyltransferase (in blue and pink, res-
pectively). The receptor structure was obtained using the PDB
database (code 1QAQ). Surflex was used to generate the poses
using flexible ligand docking. Rescoring using short optimiza-
tion of the binding pocket was performed afterwards and
the best scored pose was selected. The figure was generated
using PyMOL
structural variations dynamically, i.e. during the docking
procedure. Nevertheless, Glide can automatically gene-
rate tautomeric forms for the ligands and ZINC offers
the possibility of downloading ligands with several proto-
nation and tautomeric variants. 
To overcome the lack of generality and consistency
of different methods (see Table 3), a consensus docking
procedure has been proposed. Under this approach, the
binding modes of protein-ligand complexes are obtained
by comparing the results of several PLD software packa-
ges. Although significant increases in accuracy have
been reported, the efficiency of running several simulta-
neous screens remains a holdup point for high-through-
put virtual screening. Nevertheless, the combination of
docking methods has been applied for the in silico dis-
covery of novel chemicals (Bai et al., 2010; Choowong-
komon et al., 2010; Zhang et al., 2010). Many automated
consensus docking methods have been proposed and
developed over the years (Okamoto et al., 2010; Paul
and Rognan, 2002; Wolf et al., 2007). The Ginalski group
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focuses on the critical assessment of docking methodo-
logies and has developed VoteDock (Plewczynski et al.,
2011b) -- a consensus docking routine. Internal bench-
marking showed that the performance of the method,
in terms of both accuracy and consistency, exceeds
the performance of individual protein-ligand software. 
Post-processing of high-throughput docking results
The results obtained from HTD calculations should
be carefully post-processed and analyzed before hits are
proposed for experimental validation. For the fast gene-
ration of poses, simplified scoring functions (SF) are re-
quired and a common step after docking involves re-
scoring of the poses using more accurate models.
The Zou group recently published a detailed review on
SF (Huang et al., 2010). Here, we present a brief over-
view of current state-of-the-art and the challenges in this
field. There are three main goals of scoring: 1) to iden-
tify native binding modes, 2) to accurately predict bin-
ding affinities, and 3) to identify potential binders from
huge libraries of compounds. For high-throughput virtual
screening, the complementary prediction of affinities
and selection of binders are critical for successful re-
sults. Existing SF can be classified into three categories
depending on the parameterization methodology: 1) for-
ce-field based, derived from physical potentials, 2) empi-
rical, derived from regression analysis, and 3) know-
ledge-based, derived from statistical analysis of experi-
mentally determined complexes.
In a recent publication (Cheng et al., 2009), the per-
formance of 16 widely used SF belonging to the three ca-
tegories was analyzed and no single scoring function was
able to consistently out-perform other functions in a set
of benchmarking scenarios. Nevertheless, the know-
ledge-based methods GOLD::ASP and DrugScore and
the empirical X-Score, were found to perform better
than the other SF. In another benchmark, a set of 16 SF
was tested and it was found that a knowledge-based SF
(Huang and Zou, 2010), namely ITScore and DrugScore,
outperformed the other methods. Thus, empirical and
knowledge-based SFs are reported to have higher
success rates and better correlation with the experimen-
tal affinities than force-field based methods.
A relevant measure for HTS is the enrichment factor
– the ability of an SF to identify binders from huge libra-
ries of compounds and score them accordingly, so that
they are ranked in the first positions in the database.
Current SFs strongly depend on the nature of the target,
irrelevant of the method used to parameterize the mo-
dels. However, significant enrichment factors were ob-
served using SF of any source (Huang et al., 2010).
In an attempt to address the lack of consistency of
the methods available, multiple scoring functions can be
used to evaluate the poses. Afterwards, simple statistics
like linear combination of weighted methods or avera-
ged rank among the solutions is used to determine
the final score for each pose. By analogy to consensus
docking, this method is known as consensus scoring
(Charifson et al., 1999). The method was applied, for
example, in the in silico screening of inhibitors of Hepa-
titis C virus RNA-dependent RNA polymerase (Lin et al.,
2011). In that study, 11 scoring functions were used to
rank the HTD results. Afterwards, 14 compounds were
found to be highly scored across the rankings and se-
lected for experimental testing, to identify several novel
active compounds. Simultaneously, the Ginalski group
has recently developed HarmonyDOCK (Plewczynski et
al., 2010), a consensus scoring method for automated
evaluation of protein-ligand results. The current state of
consensus scoring and improvements in its perfor-
mance were recently analyzed (Feher, 2006).
Visualization and analysis of the results
Main limitations of PLD methods result from
simplified scoring functions and weak exploration of the
conformational space for the ligand. As a result, some
highly scored ligands may be incorrectly identified as
binders. There are some general hints that assist in the
identification of undesired hits. Due to limitations in
scoring, compounds can exhibit poses with poor physico-
chemical interactions with the binding pocket, imperfect
hydrogen-bonding network or poses based purely on
hydrophobic interactions and shape complementarity.
Solvation effects are roughly implemented in scoring
functions and, as a result, residual chains on the ligand
may not interact with the target. The generation of
poses outside the binding pocket is also common.
To exclude ligands with improper high scores, visual
inspection of VS results is required. Several software
packages are available specifically for the structural ana-
lysis of biomolecules. For example, protein-ligand com-
plexes can be visualized and inspected using the freely
available tools PyMOL, VMD (Humphrey et al., 1996),
Swiss-PDB Viewer (Guex and Peitsch, 1997) and Chime-
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ra (Pettersen et al., 2004). PyMOL was used to generate
the PLD example shown in Figure 4. 
Visual filtering of identified hits and toxicity as well
as checking the physico-chemical properties of the re-
maining compounds is strongly advised if pre-filtering
methods have not been applied prior to docking (see
section Pre-filtering). Finally, the list of virtually identi-
fied hits should be tested experimentally to determine
the activity of the compounds.
Conclusions
Structure-based VS techniques have been presented
as a promising alternative to experimental HTS. In con-
trast to experimental methods, VS strategies require prior
biological information to identify active compounds.
A general rule for VS analysis is to search only among
biologically relevant and synthetically accessible compo-
unds. The filtering step ensures rejection of compounds
that do not meet specific drug-like criteria. However,
the use of biased filters carries the risk of omitting in-
teresting ligands. Identification of compounds with parti-
cular drug-like properties may be performed by using
fingerprints or pharmacophores. These methods allow
selective searches of compounds based on information
retrieved from ligand structures or target-ligand inter-
actions.
If the structure of the target is known, ligands from
pre-filtered libraries can be virtually docked into the bin-
ding pocket using protein-ligand docking software. Struc-
ture-based VS introduces a set of drawbacks, among
which the most significant ones are poor sampling me-
thods and inaccurate scoring functions.
Notwithstanding filtering and docking caveats, VS is
a widely used tool in drug design. The method is used to
screen large libraries of compounds, complementing ex-
perimental HTS techniques in the identification of hits
with pharmacological interest. These features make VS
a useful and promising tool for modern computer-assis-
ted drug discovery and design.
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